CLINICAL_TRIALS
trial_result
· 2009-04-20
Clinical Trial Update: Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe) [Phase 3]
Summary
The Phase 3 RIO-Europe trial of rimonabant for obesity has completed over a two-year duration, sponsored by Sanofi.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Obesity | Phase 3 | Status: COMPLETED